Zobrazeno 1 - 10
of 71
pro vyhledávání: '"N M Mylov"'
Autor:
A. V. Molochkov, V. A. Molochkov, M. S. Petrova, E. A. Belousova, N. M. Mylov, T. R. Seliverstova, A. B. Sekirin
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 44, Iss 1, Pp 45-51 (2016)
Reactive arthritis is an autoimmune disease from the group of seronegative arthritis known as spondyloarthropathy. Two types of the disease are designated by this term, namely post-enter- itic (Reiter's syndrome) and venereal (urogenital) (Reiter's d
Externí odkaz:
https://doaj.org/article/c55657ed70a14b2f9814bc1eafccc7bb
Autor:
F. N. Paleev, N. P. Sanina, A. I. Makarkov, N. M. Mylov, E. I. Ostrovskiy, N. N. Khishova, O. V. Moskalets, N. R. Paleev
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 35, Pp 12-21 (2016)
Background: Autoantibodies to myocardial antigenic epitopes and corresponding autoreactive T cell clones play an important role in myocardial damage and in pathogenesis of infectious immune myocarditis. T lymphocytes subpopulations/regulatory T cells
Externí odkaz:
https://doaj.org/article/8f0b458ecf604a57a88f9e9639165975
Autor:
N. P. Sanina, F. N. Paleev, A. I. Makarkov, N. M. Mylov, E. I. Ostrovskiy, N. N. Khishova, O. V. Moskalets, N. R. Paleev
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 35, Pp 22-29 (2016)
Background: Type 17 T-helpers (Th17) were first identified more than 10 years ago. Though, there are only limited studies on the role of Th17- mediated mechanisms in the immune pathogenesis of acute myocarditis and dilative cardiomyopathy. Aim: To as
Externí odkaz:
https://doaj.org/article/f4a193952b1e4bb08adb494a21551dc9
Autor:
V. I. Shumakov, T. K. Koliashvili, N. M. Mylov, I. A. Pronchenko, V. P. Buzulina, E. N. Kozakov, A. Ya. Kormer, M. Sh. Khubutiya, N P Ermakova
Publikováno v:
Остеопороз и остеопатии, Vol 12, Iss 1, Pp 10-13 (2008)
There were analysed bone mineral density (BMD) and spine roentgenograms in 15 candidates to heart transplantation and 24 recipients of heart transplantation in early (till 1 year) as far as late (till 12 years) period following operation. BMD showed
Externí odkaz:
https://doaj.org/article/527ec5b61e2945b297b97b9f3d4e507a
Publikováno v:
Остеопороз и остеопатии, Vol 10, Iss 3, Pp 31-35 (2007)
The aim of study was tolerability and causes of discontinuation to alendronate 70 mg OW therapy in nonresearch real world setting. We prospectively analyzed 427 female patients (67+8,2years) newly prescribed with alendronate 70mg OW for postmenopausa
Externí odkaz:
https://doaj.org/article/411d7c9a0be947c0a39d5897e8348fd8
Autor:
L A MARChENKOVA, A V DREVAL', E Yu POLYaKOVA, R S TIShENINA, N M MYLOV, I P ERMAKOVA, I A PRONChENKO, V P BUZULINA, M P RUBIN
Publikováno v:
Остеопороз и остеопатии, Vol 10, Iss 3, Pp 13-20 (2007)
It is well known that clinical signs of endogenous hypercorticism including secondary osteoporosis rapidly reverse on the base of hormonal remission after radiosurgical treatment of Cushing's disease (CD). The aim of the study was to assess BMD and b
Externí odkaz:
https://doaj.org/article/5119393a786b4d9995ccafc259a29823
Autor:
A V DREVAL', L A MARChENKOVA, I V KRYuKOVA, R S TIShENINA, N V BALAShOVA, L M PORTNOY, N M MYLOV, M P RUBIN
Publikováno v:
Остеопороз и остеопатии, Vol 10, Iss 1, Pp 20-24 (2007)
The aim of this study was to assess the effectiveness of the combined treatment with calcium and middle (400 mg daily) or high doses (800 mg daily) of vitamin D for prevention of osteoporosis in postmenopausal women with osteopenia in spine. Thirty p
Externí odkaz:
https://doaj.org/article/a99148f8be414397962509d57c5963b7
Publikováno v:
Остеопороз и остеопатии, Vol 9, Iss 2, Pp 13-17 (2006)
The aim of this study was to assess effectiveness ant tolerability of alendronate in women suffered of postmenopausal osteoporosis. 15 postmenopausal women with primary osteoporosis (age 61.0±4.8 (M±σ) years) was administered alendronate in dosage
Externí odkaz:
https://doaj.org/article/080764c6287f4363a8a19354f7bf058f
Publikováno v:
Остеопороз и остеопатии, Vol 8, Iss 1, Pp 7-11 (2005)
У 30 больных (в возрасте 20-46 лет) терминальной хронической почечной недостаточностью (ТХПН), получающих лечение перитонеальным диализом (
Externí odkaz:
https://doaj.org/article/8e78932ce3ce4204bc9b8bfee864a7a8
Autor:
N M Mylov, N N Konovalova
Publikováno v:
Научно-практическая ревматология, Vol 38, Iss 4 (2000)
Externí odkaz:
https://doaj.org/article/5bc339d72d3544c5b2dd587f7c1b6c41